A Closer Look At How Single Use Consumables Drive Cost Per Therapy

Single-use consumables play a far larger role in cell and gene therapy manufacturing than their line-item status suggests. Choices made around design, qualification, supply, and change control can shape cost per therapy, influence validation risk, and either support or limit long-term scalability. From early process development through commercialization, upstream and downstream decisions affect where consumables create value and where they add avoidable complexity. A more deliberate approach can help teams identify cost and risk signals earlier, prevent closure and material constraints, and reduce supplier-related bottlenecks before they slow progress.

For manufacturers working to scale efficiently without introducing unnecessary risk, these are important considerations to evaluate before small decisions become bigger barriers.